Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
clinical trials
life sciences
national blog main
7
×
boston blog main
alnylam pharmaceuticals
boston
boston top stories
fda
rna interference
drugs
biotech
patisiran
alexion pharmaceuticals
aminolevulinic acid
deals
givosiran
hereditary transthyretin amyloidosis
national top stories
new york blog main
new york top stories
onpattro
san francisco blog main
san francisco top stories
accelerated approval
acute hepatic porphyria
acute hepatic porphyrias
akcea therapeutics
akin akinc
alirocumab
amgen
amyotrophic lateral sclerosis (als)
andrew fire
autoimmune disorders
boehringer ingelheim
cannabidiol
complement system
craig mello
dicerna pharamceuticals
dravet syndrome
epidiolex
What
drug
7
×
pharmaceuticals
7
×
alnylam
medicine
data
fda
medicines
rna
rnai
ago
approved
disease
interference
market
new
ok
pharma
second
seek
speedy
weeks
afternoon
alnylam’s
alternative
approval
autoimmune
based
battle
candidate
cannabis
caught
causing
cholesterol
cleared
deal
derivative
dicerna
epilepsy
evidence
expensive
Language
unset
Current search:
drug
×
" national blog main "
×
pharmaceuticals
×
@xconomy.com
4 years ago
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug
@xconomy.com
4 years ago
UCB Stakes Out Autoimmune Territory With $2.1B Deal for Ra Pharma
@xconomy.com
5 years ago
MedCo Touts New Data for Long-Lasting Heart Drug as Reckoning Looms
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug
@xconomy.com
5 years ago
With New Data, Alnylam Could Seek Speedy OK For Second RNAi Drug
@xconomy.com
5 years ago
Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug
@xconomy.com
5 years ago
Zogenix Epilepsy Data Sets Up Market Battle With GW’s Cannabis Drug